Premier Alternatives

Pangea Bio

Drug Discovery · Kent, United Kingdom · Founded 2021 · Privately Held (backing)

Developer of a novel medicines platform designed to treat neurological disorders. Pangea Bio is based in Kent, United Kingdom and was founded in 2021. It was valued at $80 million at its early-stage round in Oct 2024, the last priced event on record. It has raised $21.7 million across 1 recorded round; the latest was a $15.6 million Series A in Oct 2023.

PMV mark · valuation
$80.0M
Oct 2026
Priced at
its early-stage round
Oct 2024
Total raised
$21.7M
Last round
Early Stage VC (Series A)
Oct 2023

Pangea Bio key facts

as of Oct 2026
  • Developer of a novel medicines platform designed to treat neurological disorders.
  • Pangea Bio is valued at approximately $80.0M as of Oct 2026, set at its early-stage round, Oct 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $21.7M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($15.6M) in Oct 2023.
  • Notable investors include Plug and Play Tech Center, Innovate UK, Metaplanet Holdings, London & Partners., Hub71 — 19 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$80.0M

Valued at $80.0M at its early-stage round, Oct 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Pangea Bio with a free account
  • ·The complete investor list: 19 names
  • ·Watch Pangea Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Pangea Bio funding rounds

1 rounds
Oct 2023Early Stage VC (Series A)$15.6M▮
Full funding history →

Pangea Bio valuation

Pangea Bio was valued at $80 million at its early-stage round in Oct 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Pangea Bio raised?

Pangea Bio has raised $21.7 million in total; 1 of its rounds is on record. The largest on record was a $15.6 million Series A in Oct 2023.

Pangea Bio investors

19 investors are on record for Pangea Bio, including Plug and Play Tech Center, Innovate UK, Metaplanet Holdings and London & Partners.. The Series A in Oct 2023 drew 4 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Hyku Biosciences ($85 million), Linnaeus Therapeutics ($83.1 million) and Parallel Bio ($71.5 million).

About Pangea Bio

Developer of a novel medicines platform designed to treat neurological disorders. The company's platform uses artificial intelligence to uncover promising molecules from nature's diverse chemical space, enhanced by traditional human evidence of safety and efficacy, enabling healthcare providers to accelerate the development of new medicines for central nervous system disorders.

Industry
Drug Discovery
Sector
Healthcare
HQ
Kent, United Kingdom
Founded
2021
Employees
28
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.